Recce Pharmaceuticals Enters Agreement with Path BioAnalytics to Test RECCE® Compounds in Expanded SARS-CoV-2 Program

    NEXT STORY
    TRACON Pharmaceuticals Announces Filing of Protocol for ENVASARC Pivotal Trial with the FDA
    PREV STORY
    Results of Annual General Meeting
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Recce Pharmaceuticals Enters Agreement with Path BioAnalytics to Test RECCE® Compounds in Expanded SARS-CoV-2 Program

    NEXT STORY
    TRACON Pharmaceuticals Announces Filing of Protocol for ENVASARC Pivotal Trial with the FDA
    PREV STORY
    Results of Annual General Meeting
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Zogenix Presents Positive Findings on the Impact of Treatment with FINTEPLA® (ZX008) on Everyday Executive Function in Patients with Dravet Syndrome

    Data Presented During Late-Breaker Session at 72nd American Epilepsy Society Annual Meeting Additional New Analyses ...

    author_avatar
    NASDAQ Market News

    Dynavax to Present at the 2018 Cantor Global Healthcare Conference

    BERKELEY, Calif., Sept. 27, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced ...

    author_avatar
    NASDAQ Market News

    Celyad announces the approval to initiate its NKR-2 CAR-T Clinical Trial in Belgium

    MONT-SAINT-GUIBERT, Belgium, Nov. 21, 2016 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and ...

    author_avatar
    NASDAQ Market News